Scopus BioPharma Inc. (SCPS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
420 LEXINGTON AVENUE, SUITE 300 NEW YORK, NY 10170 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 124,575 | 7,942,971 | 1,832,100 | |||
| Cash and cash equivalent | 124,575 | 7,942,971 | 1,832,100 | |||
| Other undisclosed current assets | 265,425 | 241,904 | 139,639 | |||
| Total current assets: | 390,000 | 8,184,875 | 1,971,739 | |||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 2,265 | 2,840 | 2,329 | |||
| Total noncurrent assets: | 2,265 | 2,840 | 2,329 | |||
| TOTAL ASSETS: | 392,265 | 8,187,715 | 1,974,068 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 7,201,926 | 4,170,266 | 1,521,565 | |||
| Interest and dividends payable | ✕ | ✕ | 156,014 | |||
| Accrued liabilities | 4,748,128 | 3,298,218 | 659,446 | |||
| Other undisclosed accounts payable and accrued liabilities | 2,453,798 | 872,048 | 706,105 | |||
| Debt | 2,283,731 | |||||
| Other liabilities | 252,508 | |||||
| Total current liabilities: | 7,454,434 | 4,170,266 | 3,805,296 | |||
| Noncurrent Liabilities | ||||||
| Total liabilities: | 7,454,434 | 4,170,266 | 3,805,296 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | (6,564,330) | 4,017,449 | (1,831,228) | |||
| Common stock | 21,094 | 21,094 | 14,578 | |||
| Additional paid in capital | 46,518,455 | 45,538,156 | 14,224,000 | |||
| Accumulated other comprehensive income (loss) | (4,954) | (86,653) | (68,067) | |||
| Accumulated deficit | (53,064,975) | (41,455,148) | (14,501,739) | |||
| Stockholders' equity note, subscriptions receivable | (1,500,000) | |||||
| Other undisclosed equity, attributable to parent | (33,950) | |||||
| Equity, attributable to noncontrolling interest | (497,839) | |||||
| Total equity: | (7,062,169) | 4,017,449 | (1,831,228) | |||
| TOTAL LIABILITIES AND EQUITY: | 392,265 | 8,187,715 | 1,974,068 | |||
Income Statement (P&L) (USD)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Operating expenses | (11,714,877) | (27,634,619) | (10,155,846) | ||
| Operating loss: | (11,714,877) | (27,634,619) | (10,155,846) | ||
| Nonoperating income (Other Nonoperating income) | 681,210 | ||||
| Interest and debt expense | (774,679) | (706,446) | |||
| Loss from continuing operations before income taxes: | (11,714,877) | (27,728,088) | (10,862,292) | ||
| Income tax expense | (5,675,344) | (1,771,749) | |||
| Loss from continuing operations: | (11,714,877) | (33,403,432) | (12,634,041) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (33,403,432) | (12,634,041) | ||
| Other undisclosed net income | 6,450,023 | 23,496,333 | |||
| Net income (loss): | (11,714,877) | (26,953,409) | 10,862,292 | ||
| Net income attributable to noncontrolling interest | 105,050 | ||||
| Other undisclosed net income (loss) attributable to parent | (21,724,584) | ||||
| Net loss available to common stockholders, diluted: | (11,609,827) | (26,953,409) | (10,862,292) | ||
Comprehensive Income (USD)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Net income (loss): | (11,714,877) | (26,953,409) | 10,862,292 | ||
| Comprehensive income (loss): | (11,714,877) | (26,953,409) | 10,862,292 | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 105,050 | ||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 81,699 | (18,586) | (21,759,197) | ||
| Comprehensive loss, net of tax, attributable to parent: | (11,528,128) | (26,971,995) | (10,896,905) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.